The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.
Stefan Kasper
Consultant or Advisory Role - Merck
Honoraria - Merck
Other Remuneration - Merck
Markus Moehler
Consultant or Advisory Role - Merck
Honoraria - Merck
Susanna Hegewisch-Becker
Consultant or Advisory Role - Lilly; Merck; Roche
Friedrich Overkamp
No relevant relationships to disclose
Wolf O. Bechstein
No relevant relationships to disclose
Frank Kullmann
No relevant relationships to disclose
Hauke Lang
Honoraria - Merck
Michael Schoen
No relevant relationships to disclose
Victoria Smith-Machnow
No relevant relationships to disclose
Daniel Seehofer
No relevant relationships to disclose
Matthias Voehringer
No relevant relationships to disclose
Michael Geissler
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Florian Lordick
Honoraria - Med Update GmbH
Research Funding - Fresenius Biotech; GlaxoSmithKline; Merck
Peter R. Galle
No relevant relationships to disclose
Carl Christoph Schimanski
Employment or Leadership Position - Merck Serono (I)
Honoraria - Merck Serono
Research Funding - Merck Serono